Sound View Wealth Advisors Group LLC Increases Stake in Gilead Sciences, Inc. $GILD

Sound View Wealth Advisors Group LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 167.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 27,134 shares of the biopharmaceutical company’s stock after purchasing an additional 17,007 shares during the period. Sound View Wealth Advisors Group LLC’s holdings in Gilead Sciences were worth $3,008,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GILD. Price T Rowe Associates Inc. MD boosted its position in shares of Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after buying an additional 11,156,382 shares during the period. Nuveen LLC purchased a new stake in shares of Gilead Sciences in the first quarter worth approximately $620,415,000. Kingstone Capital Partners Texas LLC bought a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $238,083,000. Los Angeles Capital Management LLC lifted its stake in shares of Gilead Sciences by 422.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock worth $282,706,000 after acquiring an additional 2,040,261 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after acquiring an additional 1,942,433 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on GILD shares. UBS Group increased their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Rothschild & Co Redburn boosted their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Finally, Argus raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $127.82.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the transaction, the chief financial officer directly owned 157,055 shares in the company, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $354,240.00. Following the completion of the transaction, the insider directly owned 110,193 shares of the company’s stock, valued at approximately $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 71,500 shares of company stock valued at $8,336,040. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Down 3.7%

Shares of Gilead Sciences stock opened at $118.84 on Friday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The stock has a market cap of $147.46 billion, a price-to-earnings ratio of 23.67, a PEG ratio of 0.81 and a beta of 0.32. The firm’s 50-day moving average is $116.49 and its two-hundred day moving average is $112.22. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter in the prior year, the company earned $2.02 EPS. The company’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be issued a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.